---
title: "Sarepta Therapeutics To Announce Fourth Quarter And Full-Year 2025 Financial Results"
description: "Sarepta Therapeutics, Inc. will announce its fourth quarter and full-year 2025 financial results on February 25, 2026, after the Nasdaq closes. A conference call will follow at 4:30 p.m. E.T. to discu"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/275618041.md"
published_at: "2026-02-11T14:02:32.000Z"
---

# Sarepta Therapeutics To Announce Fourth Quarter And Full-Year 2025 Financial Results

> Sarepta Therapeutics, Inc. will announce its fourth quarter and full-year 2025 financial results on February 25, 2026, after the Nasdaq closes. A conference call will follow at 4:30 p.m. E.T. to discuss the results, which will be webcast live on the company's website. Sarepta focuses on precision genetic medicine for rare diseases, particularly Duchenne muscular dystrophy, and maintains an active investor relations section on its website for updates.

Sarepta Therapeutics Inc :

-   SAREPTA THERAPEUTICS TO ANNOUNCE FOURTH QUARTER AND FULL-YEAR 2025 FINANCIAL RESULTS

### Related Stocks

- [IBBQ.US - Invesco Nasdaq Biotechnology ETF](https://longbridge.com/en/quote/IBBQ.US.md)
- [PBE.US - Invesco Biotechnology & Genome ETF](https://longbridge.com/en/quote/PBE.US.md)
- [SBIO.US - ALPS Medical Breakthrough](https://longbridge.com/en/quote/SBIO.US.md)
- [IBB.US - iShares Biotechnology ETF](https://longbridge.com/en/quote/IBB.US.md)
- [IHE.US - iShares US Pharma](https://longbridge.com/en/quote/IHE.US.md)
- [ARKG.US - Ark Genomic Revolution ETF](https://longbridge.com/en/quote/ARKG.US.md)
- [SRPU.US - Tradr 2X Long SRPT Daily ETF](https://longbridge.com/en/quote/SRPU.US.md)
- [VHT.US - VG Health](https://longbridge.com/en/quote/VHT.US.md)
- [FBT.US - First Trust NYSE Arca Biotech Index Fd](https://longbridge.com/en/quote/FBT.US.md)
- [XBI.US - SPDR S&P Biotech](https://longbridge.com/en/quote/XBI.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives Average Recommendation of "Moderate Buy" from Analysts | Tenaya Therapeutics, Inc. (NASDAQ:TNYA) has received an average recommendation of "Moderate Buy" from five research firm | [Link](https://longbridge.com/en/news/276104250.md) |
| Neumora Therapeutics Stock Jumps, Analyst Sees Upside In Alzheimer's Treatment | William Blair upgraded Neumora Therapeutics (NASDAQ:NMRA) to Outperform, citing a favorable risk/reward after positive P | [Link](https://longbridge.com/en/news/276161520.md) |
| Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Consensus Recommendation of "Moderate Buy" from Analysts | Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has received a consensus rating of "Moderate Buy" from seven research firms. T | [Link](https://longbridge.com/en/news/276104246.md) |
| Oruka Therapeutics (NASDAQ:ORKA) Insider Joana Goncalves Sells 7,000 Shares | Oruka Therapeutics insider Joana Goncalves sold 7,000 shares at an average price of $32.37, totaling $226,590. This sale | [Link](https://longbridge.com/en/news/276182782.md) |
| Ocular Therapeutix's eye drug superior to Regeneron's Eylea in late-stage trial | Ocular Therapeutix announced that its experimental eye drug, Axpaxli, outperformed Regeneron's Eylea in a late-stage tri | [Link](https://longbridge.com/en/news/276119715.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.